Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The role of the immune microenvironment in PTLD

Erel Joffe • 30 Jun 2022
EHA 2022
B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma

Erel Joffe, MD, MSc, Tel Aviv Medical Center, Tel Aviv, Israel, and Memorial Sloan Kettering Cancer Center, New York, NY, comments on the role of the immune microenvironment in post-transplant lymphoproliferative disorder (PTLD), focusing on the impact of tumor-infiltrating lymphocytes (TILs) and T follicular helper cells (Tfh) on the disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Principle investigator on CA-4948 clinical trial for evaluation in lymphoma
Epizyme – advisory board
AstraZeneca – advisory board

More from Erel Joffe

3:08
TakeAim Lymphoma: emavusertib + ibrutinib in R/R hematological malignancies
Erel Joffe • 30 Jun 2022
2:27
Elucidating the genetic and molecular basis of DLBCL
Erel Joffe • 30 Jun 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals